Primary treatment of Hodgkin's disease

Annals of Oncology

Volumn 13, Issue SUPPL. 4, 2002, Pages 153-158

  Canellos, G P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HAIR LOSS; HODGKIN DISEASE; HUMAN; INFERTILITY; LEUKEMOGENESIS; LUNG TOXICITY; MALE; MYELODYSPLASIA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

EID: 0036435860     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf653     Document Type: Article

References (47)

1. DeVita VT Jr, Simon RM, Hubbard SM et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92: 587-595.
2. DeVita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970; 73: 881-895.
3. Sutcliffe SB, Wrigley PFM, Peto J et al. MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J 1978; 1: 679-683.
4. Selby P, Patel P, Milan S et al. Ch1VPP combination chemotherapy for Hodgkin's disease: long term results. Br J Cancer 1990; 62: 279-285.
5. Canellos GP, Young TC, DeVita VT Jr. Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy. Clin Pharm Ther 1972; 13: 750-754.
6. Young RC, Canellos GP, Chabner BA et al. Maintenance chemotherapy for advanced Hodgkin's disease in remission. Lancet 1973; 1: 1339-1343.
7. Canellos GP, DeVita VT, Arseneau JC et al. Second malignancies complicating Hodgkin's disease in remission. Lancet 1975; 1: 947-955.
8. Schilsky RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med 1980; 93: 109-114.
9. Kaldor JM, Day NE, Clarke A et al. Leukemia following Hodgkin's disease. N Engl J Med 1990; 322: 7-13.
10. Bonadonna G, Santoro A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 1982; 9: 21-35.
11. Canellos GP, Petroni GR, Barcos M et al. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. J Clin Oncol 1995; 13: 2005-2011.
12. Hagemeister FB, Cabanillas F, Velasquez WS et al. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin Oncol 1990; 17 (Suppl. 10): 34-40.
13. Bonadonna G, Valagussa P, Santoro A. Alternating non-crossresistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: a report of 8-year results. Ann Intern Med 1986; 104: 739-746.
14. Radford JA, Crowther D, Rohatiner AZS et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, Ch1VPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol 1995; 13: 2379-2385.
15. Hancock BWS, Vaughan-Hudson G, Vaughan-Hudson B et al. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation Trial. J Clin Oncol 1992; 10: 1252-1258.
16. Cosset JM, Fermé C, Noordijk EM et al. Combined modality treatment for poor prognosis stages I and II Hodgkin's disease. Semin Radiat Oncol 1996; 6: 185-195.
17. Specht L, Gray RG, Clarke MJ et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3888 patients. J Clin Oncol 1998; 16: 830-843.
18. Bodis S, Kraus MD, Pinkus G et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1997; 15: 3060-3066.
19. Vlachaki MT, Ha CS, Hagemeister FB et al. Long-term outcome of treatment for Ann Arbor stage I Hodgkin's disease: patterns of failure, late toxicity and second malignancies. Int J Radiat Oncol Biol Phys l997; 39: 609-616.
20. Sears JD, Greven KM, Ferree CR, D'Agostino RB Jr. Definitive irradiation in the treatment of Hodgkin's disease. Analysis of outcome, prognostic factors, and long-term complications. Cancer 1997; 79: 145-151.
21. Dühmke E, Franklin J, Pfreundschuh M et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001; 19: 2905-2914.
22. Cosset JM, Henry-Amar M, Meerwaldt JH et al. The EORTC trials for limited stage Hodgkin's disease. Eur J Cancer 1992; 28A: 1847-1850.
23. Wirth A, Chao M, Corry J et al. Mantle irradiation alone for clinical stage I-II Hodgkin's disease: long-term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol 1999; 17: 230-240.
24. Jones E, Mauch P. Limited radiation therapy for selected patients with pathological stages IA and IIA Hodgkin's disease. Semin Radiat Oncol 1996; 6: 162-171.
25. Carde P, Hagenbeek A, Hayat M et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11: 2258-2272.
26. Colonna P, Jais J-P, Desablens B et al. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: 10-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol 1996; 14: 1928-1935.
27. Rueda A, Alba E, Ribelles N et al. Six cycles of ABVD in the treatment of stage I and II Hodgkin's disease: a pilot study. J Clin Oncol 1997; 15: 1118-1122.
28. Straus DJ, Yahalom J, Zelenetz A et al. Results of a prospective randomized trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone versus ABVD plus radiation therapy for early stage non bulky Hodgkin's disease. Blood 2001; 98: 769a.
29. Bhatia S, Robison LL, Oberlin O et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 334: 745-751.
30. van Leeuwen FE, Klokman WJ, Hagenbeek A et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994; 12: 312-325.
31. Sankila R, Garwicz S, Olsen JH et al. Risk of subsequent malignant neoplasms among 1641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. J Clin Oncol 1996; 14: 1442-1446.
32. Bodis S, Henry-Amar M, Bosq J et al. Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols. J Clin Oncol 1993; 11: 225-232.
33. Horwich A, Specht L, Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 1997; 33: 848-853.
34. Brierley JD, Rathmell AJ, Gospodarowicz MK et al. Late relapse after treatment for clinical stage I and II Hodgkin's disease. Cancer 1997; 79: 1422-1427.
35. Hoppe RT. The management of Hodgkin's disease in relapse after primary radiation therapy. Eur J Cancer 1992; 28A: 1920-1922.
36. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478-1484.
37. Duggan D, Petroni G, Johnson J et al. MOPP/ABV versus ABVD for advanced Hodgkin's disease: a preliminary report of CALGB 8952 (with SWSOG, ECOG, NCIC). Proc Am Soc Clin Oncol 1997; 16: 12a.
38. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-1514.
39. Murray PG, Billingham LJ, Hassan HT et al. Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease. Blood 1999; 94: 442-447.
40. Sarris AH, Kliche KO, Pethambaram P et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 1999; 10: 433-440.
41. von Wasielewski R, Seth S, Franklin J et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 2000; 95: 1207-1213.
42. Diehl V, Franklin J, Paulus U et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood 2001; 98: 769a.
43. Horning SJ, Hoppe RT, Breslin S et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630-637.
44. Viviani S, Bonfante V, Santoro A et al. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am 1999; 5: 275-282.
45. Raemaekers JMM, Aleman B, Henry-Amar M et al. Involved field irradiation (IFRT) does not improve outcome in patients with stage III/IV Hodgkin's lymphoma (HL) in complete remission after MOPP/ABV (M/A): Results of the randomised EORTC trial 20884. Blood 2001; 98: 768a.
46. Horning SJ, Adhikari A, Rizk N et al. Effect of treatment for Hodgkin's disease on pulmonary function: result of a prospective study. J Clin Oncol 1994; 12: 297-305.
47. Valagussa P, Santoro A, Bonadonna G. Thyroid, pulmonary, and cardiac sequelae after treatment for Hodgkin's disease. Ann Oncol 1992; 3 (Suppl. 4): S111-S115.